Patents by Inventor Hyeongchan Oh

Hyeongchan Oh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
    Patent number: 10464919
    Abstract: The present invention relates to novel tricyclic derivative compounds, and more specifically to tricyclic derivative compounds, optical isomers thereof, racemates thereof, or pharmaceutically acceptable salts thereof, which have excellent activity against PARP-1, tankyrase-1 or tankyrase-2. The tricyclic derivative compounds, optical isomers thereof, racemates thereof or pharmaceutically acceptable salts thereof according to the present invention have inhibitory activity against PARP-1, tankyrase-1, or tankyrase-2, and thus can be effectively used for the prevention or treatment of neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic neuropathy, inflammatory diseases, osteoporosis, or cancer.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: November 5, 2019
    Assignee: Je Il Pharmaceutical Co., Ltd.
    Inventors: Hyunho Lee, Kwangwoo Chun, Bo-Young Joe, Eun Seon Kim, Eun Sung Jang, Hyeongchan Oh, Jeong-Min Kim, Jiseon Park, Hanchang Lee
  • Tricyclic Derivative Compound, Method for Preparing Same, and Pharmaceutical Composition Comprising Same
    Publication number: 20180162834
    Abstract: The present invention relates to novel tricyclic derivative compounds, and more specifically to tricyclic derivative compounds, optical isomers thereof, racemates thereof, or pharmaceutically acceptable salts thereof, which have excellent activity against PARP-1, tankyrase-1 or tankyrase-2. The tricyclic derivative compounds, optical isomers thereof, racemates thereof or pharmaceutically acceptable salts thereof according to the present invention have inhibitory activity against PARP-1, tankyrase-1, or tankyrase-2, and thus can be effectively used for the prevention or treatment of neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic neuropathy, inflammatory diseases, osteoporosis, or cancer.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 14, 2018
    Inventors: Hyunho Lee, Kwangwoo Chun, Bo-Young Joe, Eun Seon Kim, Eun Sung Jang, Hyeongchan Oh, Jeong-Min Kim, Jiseon Park, Hanchang Lee